BIOPROCESSING Viropro offers efficient, cost-effective and scalable contract laboratory and consulting services for biotechnology and biopharmaceutical research needs through its San Francisco-based subsidiary, Biologics Process Development(BPD). BPD’s services include recombinant protein expression, (cell culture, fermentation), purification, molecular biology, and/or consulting for process development and scale-up.
BIOSIMILARS Viropro International (VPI), a 100% subsidiary of Viropro, ‘houses’ Viropro’s biosimilar technologies and associated technical developments for the purpose of commercialization through external partnerships. All products are available for international partnership development without restriction. Products in development include Rituximab (Rituxan®) and Trastuzumab (Herceptin®).
GMP MANUFACTURING Viropro, through its Malaysian subsidiary, Alpha Biologics, has a new US-FDA design-reviewed 5,000m2 plant on the Penang Science Park (Malaysia) for the manufacture of biologic drugs (including biosimilars) for pre-clinical and Phase I, II and III clinical trials and early-stage commercial, focusing on mammalian cell lines. (GMP) compliant services to the worldwide pharmaceutical and biotechnology industries
Latest News.
Company Overview
Viropro, Inc., formed in 2004, focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. Company Overview.
-
Alpha Biologics is a bio-manufacturing organisation offering US FDA and European EMEA current Good Manufacturing Practices (cGMP) compliant services to the worldwide pharmaceutical and biotechnology industry.
“State-of-the-art custom-made manufacturing equipment!”
BPD is a contract laboratory and consulting services provider with extensive experience and expertise in heterologous gene expression in a variety of organisms utilizing molecular biology, biochemistry/cell biology and culture optimization-
Viropro International (VPI), a 100% subsidiary of Viropro, ‘houses’ Viropro’s biosimilar technologies and associated technical developments for the purpose of commercialization through external partnerships. Viropro is developing a range of products and manufacturing processes.
“Rituximab (Rituxan®), Trastuzumab (Herceptin®), Infliximab (Remicade®), Etanercept (Enbrel®), Bevacizumab (Avastin®)”